{"entity":{"id":"dualitybio","kind":"company","name":"Duality Biotherapeutics","aka":["DualityBio Inc."],"tldr":"Chinese ADC platform company behind BioNTech's trastuzumab pamirtecan (BNT323/DB-1303) and AI-nominated targets.","summary":"Duality Biotherapeutics, based in Shanghai and listed in Hong Kong as 9606.HK, is the Chinese antibody-drug conjugate platform company behind BioNTech's trastuzumab pamirtecan, also known as BNT323 or DB-1303, and a set of targets nominated with artificial intelligence. DB-1303 targets HER2 and is in a phase 3 in endometrial cancer with BioNTech, DB-1311 targets B7-H3, DB-1329 targets CDCP1, a target identified by AI, and all rest on its DITAC linker-payload platform. OnCo links it to HER2 and B7-H3 as targets. Whether AI-nominated ADC targets outperform the crowded conventional ones is the question DB-1329 will test. The HER2 and B7-H3 target pages carry the field context.","asOf":"2026-09-04","links":[{"label":"Official website (archived copy)","url":"https://web.archive.org/web/20211202003714/http://dualitybiotherapeutics.com/"}],"tags":[],"related":[],"cancers":[],"sections":["adcs"],"technologies":[],"targets":["her2","b7h3"],"drugs":["trastuzumab-pamirtecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05914116","nct07263594","nct06554795","nct05785741","nct06827236","nct05438329","nct05150691","nct06892548","nct06953089"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Shanghai","country":"CN","companyType":"biotech","website":"https://www.dualitybiologics.com","ticker":"9606.HK","investors":[],"funding":[]},"route":"/companies/dualitybio/","neighbours":{"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"}],"target":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"drug":[{"id":"trastuzumab-pamirtecan","kind":"drug","name":"Trastuzumab pamirtecan","route":"/drugs/trastuzumab-pamirtecan/"}],"trial":[{"id":"nct06827236","kind":"trial","name":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","route":"/trials/nct06827236/"},{"id":"nct06892548","kind":"trial","name":"A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer","route":"/trials/nct06892548/"},{"id":"nct05150691","kind":"trial","name":"A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05150691/"},{"id":"nct05914116","kind":"trial","name":"A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05914116/"},{"id":"nct06018337","kind":"trial","name":"A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Bre","route":"/trials/nct06018337/"},{"id":"nct05785741","kind":"trial","name":"A Study of DB-1310 in Advanced/Metastatic Solid Tumors","route":"/trials/nct05785741/"},{"id":"nct07263594","kind":"trial","name":"A Study of DB-1324 in Advanced/Metastatic Gastrointestinal Tumors","route":"/trials/nct07263594/"},{"id":"nct06265428","kind":"trial","name":"A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer","route":"/trials/nct06265428/"},{"id":"nct06953089","kind":"trial","name":"DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors","route":"/trials/nct06953089/"},{"id":"nct05438329","kind":"trial","name":"First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors","route":"/trials/nct05438329/"},{"id":"nct06554795","kind":"trial","name":"First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors","route":"/trials/nct06554795/"}]}}